Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab re-treatment criteria study in myopic choroidal neovascularization
2013-003334-33Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in myopic choroidal neovascularisation (mCNV) and myopic maculopathy (MM), sponsored by Novartis. Primary endpoint: Criteria driving re-treatment with ranibizumab. Started Oct 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
myopic choroidal neovascularisation (mCNV)myopic maculopathy (MM)
Beyond the preview
Go deeper on 2013-003334-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003334-33.